Stay updated on Imprime PGG+Pembrolizumab in Melanoma & TNBC Clinical Trial
Sign up to get notified when there's something new on the Imprime PGG+Pembrolizumab in Melanoma & TNBC Clinical Trial page.

Latest updates to the Imprime PGG+Pembrolizumab in Melanoma & TNBC Clinical Trial page
- ChecktodayChange DetectedAdded revision tag v3.5.0 and removed revision tag v3.4.3.SummaryDifference0.0%

- Check7 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3, reflecting a minor update to the page version. It does not affect the study content.SummaryDifference0.0%

- Check14 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check36 days agoChange DetectedRevision updates: added v3.4.2 and removed v3.4.1. These changes are minor and do not affect study content, eligibility criteria, or results; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check43 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check50 days agoChange DetectedIntroduced a glossary toggle and updated metadata labels, including capitalization changes to 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data', with the revision level updated to v3.4.0.SummaryDifference0.2%

- Check65 days agoChange DetectedA minor revision update was applied (from v3.3.3 to v3.3.4); no changes to study content, eligibility, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Imprime PGG+Pembrolizumab in Melanoma & TNBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Imprime PGG+Pembrolizumab in Melanoma & TNBC Clinical Trial page.